Collaborators

In December 2014, Janssen entered into a collaboration agreement to develop and commercialize MGD011 (CD19 x CD3). MacroGenics retains co-promotion rights in the U.S., and may elect to fund a portion of late-stage clinical development in exchange for a U.S. and Canada profit share. Learn more

In May 2014, Takeda entered into a collaboration agreement to develop and commercialize MGD010, a DART that simultaneously targets CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently in pre-clinical development for the treatment of autoimmune diseases. Learn more

Gilead Sciences entered into a license agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at up to four undisclosed targets. MacroGenics retains certain rights in non-U.S., non-European major markets for one program. Learn more

Boehringer Ingelheim entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas. These drug candidates will be based on MacroGenics’ Dual-Affinity Re-Targeting (DART™) platform and will be directed against up to ten combinations of molecular targets. Learn more

Under the terms of the September 2012 agreement, MacroGenics retains full development and commercialization rights to three oncology DARTs in North America, Japan, Korea and India, while Servier has an option to obtain an exclusive license covering the rest of the world. Learn more

In July 2010, Green Cross entered into a collaboration agreement with MacroGenics for the exclusive development and commercialization of MGAH22 (anti-HER2 monoclonal antibody) in Korea. A multinational Phase I study will be conducted in both the US and Korea.
Under the terms of the December 2011 agreement, MacroGenics retains full development and commercialization rights to MGA271 in North America, Japan, Korea and India, while Servier has an option to obtain an exclusive license covering the rest of the world. Learn more